The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
HOME > REGULATORY
REGULATORY
- Ryukaikon’s Working Team Prepares to Start Operations by End of June; Beginning with Exchange of Opinions between JPWA, NPhA
June 13, 2012
- With Consumption Tax Hike in 2015, “Focus on Whether to Conduct Market Price Survey”: EAD Director Kamata
June 12, 2012
- PAFSC Committee Gives Green Light to OTC Switching of Hyaluronate Sodium
June 11, 2012
- Committee on Non-Prescription Drugs Recommends Approval for Switch OTC Versions of Allegra
June 11, 2012
- Medical Community Expresses Caution on Deferment of Experimental Animal Regulations by DPJ
June 8, 2012
- Gov’t Council Finalizes 5-Year Medical Innovation Strategy Calling for Creation of Drug Discovery Support Network
June 8, 2012
- Expert Subcommittee Begins Discussions on Pricing of Long-Listed Drugs with Focus on Differences from Generic Prices
June 8, 2012
- Drug Cost Ratio in FY2009 was 22.3%, Up 1.1 Points from Previous Year: MHLW
June 8, 2012
- Local Governments Express Concern for IPV Price at 5,450 Yen
June 7, 2012
- Survey Highlights Successful Efforts of 5 Prefectures to Promote Generic Drug Use
June 6, 2012
- PAFSC 1st Committee on New Drugs Recommends Approval for Fibromyalgia Indication for Lyrica
June 5, 2012
- DPJ’s Proposal on 5-Year Innovation Strategy Calls for Subsidies to Reduce Consultation, Review Fees
June 4, 2012
- PAFSC’s 2nd Committee Recommends Approval for Pfizer Japan’s Axitinib
June 4, 2012
- MHLW Announces Addition of 5 APIs/8 Products to NHI Price List
June 1, 2012
- Cost-Effective Assessments “Not Appropriate” for Everything: MED Director Suzuki
May 31, 2012
- DPJ Proposal to Amend PAL Would Mandate Reporting of Package Inserts
May 31, 2012
- Specific Targets for New 5-Year Clinical Trial Activation Plan Expected by Late August
May 31, 2012
- Nakajima of HPB Calls on Kampo Association to Collect Data, Make Case for Favorable Re-Pricing
May 30, 2012
- MHLW Adds 8 APIs/10 Products Including Xalkori to NHI Price List
May 30, 2012
- MHLW Sets Up Office for Promotion of Medical Innovation to Realize New 5-Year Strategy
May 29, 2012
ページ
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…